TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis

MLA

Daïen, Claire Immediato, et al. “TGF Beta1 Polymorphisms Are Candidate Predictors of the Clinical Response to Rituximab in Rheumatoid Arthritis.” Joint Bone Spine, vol. 79, no. 5, Oct. 2012, pp. 471–75. EBSCOhost, https://doi.org/10.1016/j.jbspin.2011.10.007.

APA

Daïen, C. I., Fabre, S., Rittore, C., Soler, S., Daïen, V., Tejedor, G., Cadart, D., Molinari, N., Daurès, J.-P., Jorgensen, C., & Touitou, I. (2012). TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine, 79(5), 471–475. https://doi.org/10.1016/j.jbspin.2011.10.007

Chicago

Daïen, Claire Immediato, Sylvie Fabre, Cécile Rittore, Stephan Soler, Vincent Daïen, Gautier Tejedor, Doris Cadart, et al. 2012. “TGF Beta1 Polymorphisms Are Candidate Predictors of the Clinical Response to Rituximab in Rheumatoid Arthritis.” Joint Bone Spine 79 (5): 471–75. doi:10.1016/j.jbspin.2011.10.007.